Elke Firat

[Samuel Hume @DrSamuelBHume]

Top 5 advances in medicine from March (🧵)

1. Human cells make their own antibiotics

Proteins that are no longer needed are broken down in the proteasome, but it turns out that some of the peptides it produces are repurposed as antibiotics

These antibiotic peptides help us fight infection, but could also be used as therapeutics

The top hit (which is derived from a serine/threonine phosphatase) kills a range of bacteria, including Pseudomonas and E. coli, and stopped mice dying from sepsis just as well as a conventional antibiotic

https://t.co/AJRakhYPPb

[Nature Reviews Cancer @NatureRevCancer]

NEW content online! Cross-priming in cancer immunology and immunotherapy https://t.co/j3bqHUJ8ma

[nature @Nature]

The bidirectional transfer of mitochondria between cancer and immune cells is a newly discovered mechanism that thwarts anticancer defences

https://t.co/wFndMv4oV0

[Cancer Cell @Cancer_Cell]

Online Now: Interleukin-1α release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity https://t.co/lqUlRMguQc

[Haydn Kissick @HaydnKissick]

Check out our latest paper “Differentiation fate of a stem-like CD4 T cell control immunity to cancer”, led by @Maria_Carden1 now live @Nature https://t.co/CrbGlEdQja . This work examines how CD4 T cell differentiation dictates the outcome of the cancer response. Thread below

[Elke Firat @ElkeFirat]

@RenLuo_RAD Congratulations 🥳

[Ren Luo, MD PhD @RenLuo_RAD]

Happy to get 35under35 of Chinese Society of Clinical Oncology 2024!

[Cancer Cell @Cancer_Cell]

Online Now: Perilymphatic regulatory T cell-dendritic cell interactions represent a novel axis of immunosuppression in cancer https://t.co/3R3CUrarM4

[Nature Medicine @NatureMedicine]

In the largest report of #CARTcells in patients with solid tumors, autologous CLDN18.2-targeting CART therapy had overall response of 42.2% and disease control rate of 91.1% in patients with advanced CLDN18.2-positive gastrointestinal cancers
https://t.co/KO4lxlvicz

[Cancer Cell @Cancer_Cell]

Online Now: Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors https://t.co/ZmHZ9oQS45

[Cancer Cell @Cancer_Cell]

Interruption of the intratumor CD8+ T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy https://t.co/gE4fuQ5Uus

[Waggoner Lab @LabWaggoner]

NK-cell therapies are safer than T-cell therapies and offer other advantages but require upgrades to overcome their limited lifespan and susceptibility to immunosuppression @Nature @ImmYounology
https://t.co/ofbnn1IDv9

[Kateryna🇺🇦 @KatOnyshchenko]

Check out our new paper shedding light on the mechanism of lenalidomide-mediated improvement of the RT-induced abscopal effect in solid tumor models, published this week in Theranostics 👏👏👏@RenLuo_RAD @ElkeFirat @GabiNiedermann @RadOnc_UKF @DKTK_
https://t.co/4B8vdNwf05

[Waggoner Lab @LabWaggoner]

REVIEW @ImmunityCP
Interleukin-2 signaling in the regulation of T cell biology in autoimmunity and cancer
https://t.co/ALcCGbR3lQ

[Nature Reviews Cancer @NatureRevCancer]

And the moment you've all been waiting for... Our top downloaded article in 2023: Mechanisms driving the immunoregulatory function of cancer cells
by Antoinette van Weverwijk & @deVisserKarin https://t.co/NvE4bSML1N @NatResCancer @NKI_nl @oncodeinstitute #NRCtop10of2023 https://t.co/xA6sUzOkYj

[Immunity @ImmunityCP]

The cancer-immunity cycle: Indication, genotype, and immunotype https://t.co/fq8zV83PQB

[Ren Luo, MD PhD @RenLuo_RAD]

Thanks @jitcancer

[Kateryna🇺🇦 @KatOnyshchenko]

Thesis defended, PhD journey complete! ✅🎓 Ready to dive into new, exciting adventures and opportunities 🎉

[Elke Firat @ElkeFirat]

@KatOnyshchenko Congratulations!!!🥳

[Ren Luo, MD PhD @RenLuo_RAD]

Thank the nice moderators @HMcGeeMDPhD and Arta Monjazeb at #ASTRO2023 on innate immunity and TIME! And nice discussion with @ARajkumarMD and Tissana
Prasartseree about Lattice radiation